UDI-001
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cerebral Palsy
Conditions
Cerebral Palsy, Periventricular Leukomalacia
Trial Timeline
Jun 2, 2021 → Feb 15, 2024
NCT ID
NCT04873752About UDI-001
UDI-001 is a phase 1/2 stage product being developed by Rohto Pharmaceutical for Cerebral Palsy. The current trial status is completed. This product is registered under clinical trial identifier NCT04873752. Target conditions include Cerebral Palsy, Periventricular Leukomalacia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04873752 | Phase 1/2 | Completed |
Competing Products
20 competing products in Cerebral Palsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mouse nerve growth factor | Sun Pharmaceutical | Approved | 85 |
| Edaravone Dexborneol + Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Oral Glycopyrrolate Liquid | Shionogi | Phase 3 | 77 |
| recombinant human erythropoietin alfa + 0.9% NaCl | Johnson & Johnson | Phase 2/3 | 65 |
| NXY-059 | AstraZeneca | Phase 3 | 77 |
| NXY-059 | AstraZeneca | Phase 2 | 52 |
| Rosuvastatin | AstraZeneca | Approved | 85 |
| NXY-059 | AstraZeneca | Phase 3 | 77 |
| Comparator: Placebo + Comparator: MK0724 | Merck | Phase 2 | 52 |
| Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mg | Merck | Phase 2 | 52 |
| Recombinant Factor VIIa + Biological/Vaccine: Placebo | Novo Nordisk | Phase 3 | 76 |
| Recombinant Activated Factor VII (rFVIIa) + Placebo | Novo Nordisk | Phase 3 | 76 |
| Ponezumab | Pfizer | Phase 2 | 51 |
| PF-05230907 | Pfizer | Phase 1 | 32 |
| Azithromycin + Pyrimethamine + Leucovorin calcium | Pfizer | Phase 1 | 32 |
| clopidogrel (SR25990C) | Sanofi | Approved | 84 |
| Intrarectal quinine | Sanofi | Phase 3 | 76 |
| Piracetam | UCB | Approved | 82 |
| Placebo + ALN-APP | Alnylam Pharmaceuticals | Phase 2 | 49 |
| CN-105 | Tiantan Bio | Phase 2 | 49 |